Synlogic reaches end of the road for synthetic biology quest after pivotal data disappoint
Synlogic is closing out its 10-year quest in harnessing synthetic biology to create new therapies after deciding that its lead program is unlikely to succeed in a pivotal study.
The biotech will cease operations and lay off most of its employees — more than 90% — leaving only enough staffers to assist in winding down the study. The remaining team will also help explore strategic alternatives, including but not limited to M&A, asset deals or outright dissolution.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.